- Home
- PIM vs CATX Comparison
PIM vs CATX Comparison
Compare PIM & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | CATX |
|---|---|---|
| Founded | 1988 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.9M | 161.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIM | CATX |
|---|---|---|
| Price | $3.33 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 57.5K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $1.60 |
| 52 Week High | $3.28 | $5.39 |
Technical Indicators
Market Signals| Indicator | PIM | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 44.65 |
| Support Level | $3.28 | $2.07 |
| Resistance Level | $3.39 | $2.31 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 37.43 | 70.09 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.